0001564590-22-003054.txt : 20220128 0001564590-22-003054.hdr.sgml : 20220128 20220128170624 ACCESSION NUMBER: 0001564590-22-003054 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20220125 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220128 DATE AS OF CHANGE: 20220128 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Metacrine, Inc. CENTRAL INDEX KEY: 0001634379 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 472297384 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39512 FILM NUMBER: 22569871 BUSINESS ADDRESS: STREET 1: 3985 SORRENTO VALLEY BLVD., SUITE C CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-369-7800 MAIL ADDRESS: STREET 1: 3985 SORRENTO VALLEY BLVD., SUITE C CITY: SAN DIEGO STATE: CA ZIP: 92121 8-K 1 mtcr-8k_20220125.htm 8-K mtcr-8k_20220125.htm
false 0001634379 0001634379 2022-01-25 2022-01-25

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 25, 2022

 

Metacrine, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-39512

47-2297384

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 

 

 

3985 Sorrento Valley Blvd., Suite C

San Diego, California

 

92121

(Address of Principal Executive Offices)

 

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (858) 369-7800

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

 

MTCR

 

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒ 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒ 

 

 

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 25, 2022, Catherine Lee notified the Company that she will resign from her position as EVP, General Counsel and Corporate Secretary, effective as of January 28, 2022 (“Resignation Date”), to pursue another opportunity. In connection with Ms. Lee’s resignation, the Company entered into a separation and consulting agreement with Ms. Lee (“Separation Agreement”) whereby, among other things, Ms. Lee will agree to a general release of claims in favor of the Company and its affiliates as well as customary confidentiality provisions. Effective immediately following the Resignation Date, Ms. Lee will provide consulting services to the Company through August 30, 2022, unless terminated by either Ms. Lee or the Company upon two weeks’ prior written notice. During this consulting period, Ms. Lee will be paid a consulting fee equal to $8,500 per month and will be available for consultation as requested for up to 10 hours per month and continued vesting and exercisability of any outstanding and unvested equity awards in accordance with the terms and conditions of the applicable award agreements.

 

The foregoing description of the Separation Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Separation Agreement, which is attached hereto as Exhibit 99.1 and incorporated herein by reference.

9.01 Financial Statements and Exhibits.

 

(d)

 

The following exhibit is furnished with this Current Report.

 

Exhibit

Number

 

Description

99.1

 

Separation and Consulting Agreement dated as of January 27, 2022, between Metacrine, Inc. and Catherine Lee.

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document).

1

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

Metacrine, Inc.

 

 

 

 

Date: January 28, 2022

 

By:

/s/ Patricia Millican

 

 

 

Patricia Millican

 

 

 

Chief Financial Officer

 

 

 

(Principal Financial and Accounting Officer)

 

2

 EX-99.1 2 mtcr-ex991_45.htm EX-99.1 mtcr-ex991_45.htm

 

Exhibit 99.1

 

METACRINE, INC.

 

SEPARATION AND CONSULTING AGREEMENT

This Separation and Consulting Agreement (this “Agreement”) is effective as of January 27, 2022 (“Effective Date”), by and between Metacrine, Inc., a Delaware corporation (the “Company”) located at 3985 Sorrento Valley Blvd, Suite C, San Diego, California 92121, and Catherine Lee (“Lee” or “Consultant”) an individual with the address on file with the Company.

 

1.Separation Date.  The Company and Lee acknowledge and agree that Lee’s last day of work with the Company will be January 28, 2022 (the “Separation Date”).  On or before the Separation Date, the Company will pay Lee all accrued salary, and all accrued and unused vacation (if any) earned through the Separation Date, subject to standard payroll deductions and withholdings.  Lee is entitled to these payments regardless of whether or not this Agreement has been signed.

2.Consulting Agreement.  Provided that Consultant timely signs and does not revoke Consultant’s acceptance of the Release of Claims Agreement (“Release”) attached as Exhibit A, Consultant will serve as a consultant to the Company beginning on the Separation Date, and ending on August 30, 2022 (“Term”).  As a consultant, Consultant will be responsible for assisting the Company in any areas of Consultant’s expertise and with other projects to be determined by mutual agreement between Consultant and the Chief Executive Officer, as reasonably requested by the Company (collectively, the “Services”). It is anticipated that Consultant will provide up to ten (10) hours of Services per month.  Consultant may not subcontract or otherwise delegate Consultant’s obligations under this Agreement without Company’s prior written consent as it in its sole discretion determines.  Consultant shall at all times use best efforts and all due diligence in performing the Services. All Services shall be performed in accordance with (i) generally accepted professional standards and applicable laws, rules and regulations; (ii) Company policies and procedures; and (iii) to Company’s reasonable satisfaction. To the extent any of the Services require Consultant to possess any professional or other licenses, Consultant shall maintain such licensure(s) in good standing throughout the Term (as defined herein).  Consultant understands that if the Release does not take effect within 29 days from the date on which Consultant received the Release, the Term will automatically terminate and Consultant will not be eligible for any of the benefits set forth in this Agreement or the Release.

3.Consulting Fees.  Provided that Consultant: (i) performs the Services to the Company’s satisfaction (as determined by the Company in its sole discretion); and (ii) complies with Consultant’s contractual obligations to the Company (including, without limitation, the obligations set forth herein), then the Company will pay Consultant consulting fees equal to $8,500 per month. The Company will reimburse reasonable out-of-pocket expenses, if any, incurred by Consultant in the performance of the Services provided such are pre-approved in writing by the Company’s CEO (“Authorized Expenses”). Consultant shall submit invoices to Company on a monthly basis for all Services provided and Authorized Expenses incurred during the preceding month. Each invoice shall include a detailed description of the Services performed delineated by project or task, as applicable, and a detailed description of the Authorized Expenses with all required receipts. All invoices must be sent to: ap@metacrine.com. Payment terms are net thirty (30) days. Consultant understands that Company will report Consultant’s compensation and reimbursed expenses under this Agreement to the extent Company, in its sole opinion, believes that it is required to do so by applicable laws or regulations.

3.1Equity.  Contingent on Consultant’s execution of the Release and subject to Consultant’s compliance with the terms and conditions of this Agreement, and the post-employment obligations set forth herein, including without limitation, non-solicitation, confidentiality, intellectual property, and return of property, in consideration of amounts in excess of the minimum entitlements under applicable law:

(a)During Consultant’s employment with the Company, Consultant was granted performance restricted stock units (“PRSUs”) and options (“Options”) to purchase shares of the Company's common stock (collectively, the “Equity”). This Agreement is intended to commence in a manner such that Consultant remains in "continuous service" with the Company after the Separation Date. Thus, during the Term of this Agreement, the vesting on Consultant’s Equity will remain unchanged, and will continue to vest as set forth in the governing equity agreements. However, notwithstanding anything to the contrary set forth in the applicable Equity agreements, vesting of Consultant’s Equity will cease as of the date of termination of this Agreement.  Consultant’s rights to exercise any vested Options shall be modified such that the exercisability of Consultant’s Options shall terminate as of nine (9) months from the date of termination of this Agreement.

4.Independent Contractor Relationship.  Consultant’s relationship with Company will be that of an independent contractor and not an employee of Company for any purpose.  Consultant is not the agent of Company and is not authorized to make any representation, contract, or commitment on behalf of Company.  Consultant will not be entitled to any of the benefits that Company may make available to its employees.  Because Consultant is an independent contractor, Company will not

1.

 

withhold or make payments for social security, make unemployment insurance or disability insurance contributions, or obtain worker’s compensation insurance on Consultant’s behalf.  Consultant accepts exclusive liability for complying with all applicable state and federal laws governing self-employed individuals and agrees to indemnify and defend Company against any and all such taxes or contributions, including penalties and interest.  

5.

Confidentiality.

5.1Protection of Information.  Consultant agrees that during the term of the Agreement and thereafter, not to use or disclose any confidential or proprietary information or materials of the Company that was obtained or developed in the course of performing the Services.  Any and all work product created in the course of performing the Services will be the sole and exclusive property of the Company.  Consultant hereby assigns to the Company all right, title, and interest in and all inventions, techniques, processes, materials and other intellectual property developed in the course of performing consulting services for the Company.

5.2Proprietary Information Obligations.  Both during and after employment, Consultant acknowledges Consultant’s continuing obligations under Consultant’s Proprietary Information and Inventions Agreement, including obligations not to use or disclose any confidential or proprietary information of the Company.  A copy of Consultant’s Proprietary Information and Inventions Agreement is attached hereto as Exhibit B.

5.3Return of Company Property and Confidential Information. To the extent that Consultant is permitted to retain any Company property or Proprietary Information that is necessary for the performance of Services, and any such documents/equipment/Proprietary Information retained for that purpose and any copies or other tangible or electronic embodiments thereof must be returned to the Company by the close of business on the last date of the Term, or earlier if requested by the Company (and provide certification confirming such return); provided that  in the event Consultant has any a copy on Consultant’s standard computer backup systems, if not possible to destroy those copies, Consultant must ensure that access to those backup copies is denied and such copies are subject to the ongoing obligations of nondisclosure and nonuse.

5.4Publications/Representation of Company. Consultant shall not present or publish, or submit for publication, any work describing or resulting from the Services without the prior written consent of Company.  

6.Compliance with Law. Each party shall perform its obligations under this Agreement in compliance with all applicable federal and state laws, regulations, guidance, and ethical standards.

7.Termination.

7.1Term.  The term of this Agreement shall commence on the Effective Date and shall remain in full force and effect during the Term, unless terminated earlier as set forth herein.

7.2Termination of Agreement.  Either Party may terminate this Agreement for convenience, for any or no reason, at any time upon ten (10) days prior written notice to the other Party.  Either party may terminate this Agreement for cause upon written notice to the other party, if the other party breaches this Agreement and does not cure the breach within thirty (30) days following receipt of written notice thereof from the non-breaching party.  Such right to terminate this Agreement for cause shall be in addition to any other remedies available to the terminating party at law or in equity.

7.3Noninterference with Business.  During the term of this Agreement, Company and Consultant agree not to solicit or induce any employee or independent contractor to terminate or breach an employment, contractual, or other relationship with the non-soliciting party.

7.4Pre-Existing Rights; Survival.  The termination of this Agreement shall not affect in any way the rights and obligations of either party which have accrued prior to such event or in connection therewith.  The following provisions shall survive termination of this Agreement and all definitions necessary to interpret the foregoing:  Sections 3.1, 5, 7.3, 7.4 and 9.

8.

General Provisions.

8.1Governing Law.  This Agreement will be governed by and construed in accordance with the laws of the State of California as applied to transactions taking place wholly within California between California residents.  

8.2Severability.  In case any one or more of the provisions contained in this Agreement shall, for any reason, be held to be invalid, illegal, or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect the other provisions of this Agreement, and this Agreement shall be construed as if such invalid, illegal, or unenforceable provision had

 

2.

 

never been contained herein.  If moreover, any one or more of the provisions contained in this Agreement shall for any reason be held to be excessively broad as to duration, geographical scope, activity, or subject, it shall be construed by limiting and reducing it, so as to be enforceable to the extent compatible with the applicable law as it shall then appear.

8.3No Assignment.  This Agreement may not be assigned by Consultant without Company’s consent, and any such attempted assignment shall be void and of no effect. The Company may assign its rights and obligations hereunder to an affiliate or to any person or entity that succeeds to all or substantially all of the Company’s business to which this Agreement relates, whether by merger, acquisition or other means.

8.4Notices.  All notices, requests, and other communications under this Agreement must be in writing and must be mailed by registered or certified mail, postage prepaid and return receipt requested, or delivered by hand to the party to whom such notice is required or permitted to be given.  If mailed, any such notice will be considered to have been given five (5) business days after it was mailed, as evidenced by the postmark.  If delivered by hand, any such notice will be considered to have been given when received by the party to whom notice is given, as evidenced by written and dated receipt of the receiving party.  The mailing address for notice to either party will be the address shown on the signature page of this Agreement.  Either party may change its mailing address by notice as provided by this section.

8.5Legal Fees.  If any dispute arises between the parties with respect to the matters covered by this Agreement which leads to a proceeding to resolve such dispute, the prevailing party in such proceeding shall be entitled to receive its reasonable attorneys’ fees, expert witness fees, and out-of-pocket costs incurred in connection with such proceeding, in addition to any other relief it may be awarded.

8.6Injunctive Relief.  A breach of any of the promises or agreements contained in this Agreement may result in irreparable and continuing damage to Company for which there may be no adequate remedy at law, and Company is therefore entitled to seek injunctive relief as well as such other and further relief as may be appropriate.

8.7Waiver.  No waiver by Company of any breach of this Agreement shall be a waiver of any preceding or succeeding breach.  No waiver by Company of any right under this Agreement shall be construed as a waiver of any other right.  Company shall not be required to give notice to enforce strict adherence to all terms of this Agreement.

8.8Entire Agreement.  This Agreement is the final, complete, and exclusive agreement of the parties with respect to the subject matter hereof.  This Agreement supersedes all prior discussions between the parties on its subject matter.  No modification of or amendment to this Agreement, nor any waiver of any rights under this Agreement, will be effective unless in writing and signed by the party to be charged.  The terms of this Agreement will govern all Services undertaken by Consultant for Company.

[REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK]


 

3.

 

In Witness Whereof, the parties have caused this Separation and Consulting Agreement to be executed by their duly authorized representative.

 

Metacrine, Inc.

 

 

By: /s/ Preston Klassen_____________

       Preston Klassen, President and CEO

 

Address:   3985 Sorrento Valley Blvd, Suite C, San Diego, CA 92121

 

 

Catherine Lee

 

 

By:  /s/ Catherine Lee____________

        Catherine Lee

 

 

 

4.

 

 

EXHIBIT A

 

RELEASE OF CLAIMS AGREEMENT

 

This Release of Claims Agreement (“Release”) is made by and between Metacrine, Inc. (“Employer”) and Catherine Lee (“Employee”).

1.Consideration. Employee acknowledges and agrees that the Separation and Consulting Agreement constitutes adequate legal consideration for the promises and representations made by Employee in this Release.    

2.General Release.

2.1Employee unconditionally, irrevocably and absolutely releases and discharges Employer, and any parent and subsidiary corporations, divisions and other affiliated entities of Employer, past and present, as well as Employer’s past and present employees, officers, directors, agents, attorneys, successors and assigns of Employer (collectively, “Released Parties”), from all claims related in any way to the transactions or occurrences between them to date to the fullest extent permitted by law, including but not limited to, any losses, liabilities, claims, demands and causes of action, known or unknown, suspected or unsuspected, arising directly or indirectly out of or in any way connected with Employee’s employment with Employer, or the termination of Employee’s employment.  This release is intended to have the broadest possible application and includes, but is not limited to, any tort, contract, common law, constitutional or other statutory claims, as well as alleged violations of the California Labor Code, the California Family Rights Act, the federal Family and Medical Leave Act, Title VII of the Civil Rights Act of 1964, the Age Discrimination in Employment Act of 1967, the California Fair Employment and Housing Act, the Americans with Disabilities Act, the laws of any state in which Employee performed services for Employer, and all claims for attorneys’ fees, costs and expenses.  However, this release shall not apply to claims for workers’ compensation benefits, unemployment insurance benefits, or any other claims that cannot, by statute, lawfully be waived by this Agreement.

2.2Employee acknowledges that Employee may discover facts or law different from, or in addition to, the facts or law that Employee knows or believes to be true with respect to the claims released in this Agreement and agrees, nonetheless, that this Agreement and the release contained in it shall be and remain effective in all respects notwithstanding such different or additional facts or the discovery of them.  Employee further acknowledges that, during employment, Employee has not made any claims or allegations to Employer related to sexual assault or abuse, harassment, discrimination or retaliation.

2.3Employee declares and represents that Employee intends this Agreement to be complete and not subject to any claim of mistake, and that the release herein expresses a full and complete release, and Employee intends the release herein to be final and complete.  Employee executes this release with the full knowledge that this release covers all possible claims against the Released Parties, to the fullest extent permitted by law.  The parties acknowledge and agree that this Agreement is a negotiated settlement agreement and Employee’s acceptance of this Agreement is voluntary, deliberate and informed.

2.4Employee expressly waives Employee’s right to recover any type of personal relief from Employer, including monetary damages or reinstatement, in any administrative action or proceeding, whether state or federal, and whether brought by Employee or on Employee’s behalf, related in any way to the matters released herein.

3.California Civil Code Section 1542 Waiver.  Employee expressly acknowledges and agrees that all rights under Section 1542 of the California Civil Code are expressly waived.  Section 1542 provides:

A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR RELEASED PARTY.

Employee understands that Employee is a “releasing party” within the meaning of Section 1542.

4.Representation Concerning Filing of Legal Actions.  Employee represents that, as of the date of this Agreement, Employee has not filed any lawsuits, charges, complaints, petitions, claims or other accusatory pleadings against Employer or any of the other Released Parties in any court of law.  Employee further agrees that, to the fullest extent permitted by law, Employee will not prosecute in any court, whether state or federal, any claim or demand of any type related to the matters released above, it being the intention of the parties that with the execution of this release, the Released Parties will be absolutely, unconditionally and forever discharged of and from all obligations to or on behalf of Employee related in any way to the matters discharged herein.  Nothing in this paragraph or this Agreement limits Employee’s ability to file a charge or complaint with the

1.

 

Equal Employment Opportunity Commission, the National Labor Relations Board, the Occupational Safety and Health Administration, the Securities and Exchange Commission or any other federal, state or local governmental agency or commission (“Government Agencies”).  Employee further understands that this Agreement does not limit Employee’s ability to communicate with any Government Agencies or otherwise participate in any investigation or proceeding that may be conducted by any Government Agency, including providing documents or other information, without notice to Employer.  

5.No Admissions.  By entering into this Agreement, the Released Parties make no admission that they have engaged, or are now engaging, in any unlawful conduct.  The parties understand and acknowledge that this Agreement is not an admission of liability and shall not be used or construed as such in any legal or administrative proceeding.

6.Waiver Procedures Under the Older Workers Benefit Protection Act.  This Agreement is intended to satisfy the waiver and release requirements of the Older Workers Benefit Protection Act, 29 U.S.C. sec. 626(f).  The following general provisions, along with the other provisions of this Agreement, are agreed to for this purpose:

6.1Employee acknowledges and agrees that Employee has read and understands the terms of this Agreement.

6.2Employee is advised that Employee should consult with an attorney before executing this Agreement, and Employee acknowledges that Employee has obtained and considered any legal advice Employee deems necessary, such that Employee is entering into this Agreement freely, knowingly, and voluntarily.

6.3Employee acknowledges that Employee has been given at least 21 days in which to consider whether or not to enter into this Agreement.  Employee understands that, at Employee’s option, Employee may elect not to use the full 21-day period.

6.4This Agreement shall not become effective or enforceable until the eighth day after Employee signs this Agreement.  In other words, Employee may revoke acceptance of this Agreement within seven days after the date Employee signs it.  Employee's revocation must be in writing and received by Theresa Lowry, EVP, Human Resources, on or before the seventh day in order to be effective.  If Employee does not revoke acceptance within the seven-day period, Employee's acceptance of this Agreement shall become binding and enforceable on the eighth day (“Effective Date”).

6.5This Agreement does not waive or release any rights or claims that Employee may have under the Age Discrimination in Employment Act that arise after the execution of this Agreement.

7.Severability.  In the event any provision of this Agreement shall be found unenforceable by a court of competent jurisdiction, the provision shall be deemed modified to the extent necessary to allow enforceability of the provision as so limited, it being intended that the Released Parties shall receive the benefits contemplated herein to the fullest extent permitted by law.  If a deemed modification is not satisfactory in the judgment of such court, the unenforceable provision shall be deemed deleted, and the validity and enforceability of the remaining provisions shall not be affected thereby.  

8.Return of Employer Property.  By signing this Agreement, Employee represents and warrants that with the exception of Employee’s laptop, Employee has or will have returned Company property no later than the Effective Date, including any Employer issued or provided credit cards, vehicles, tangible property and equipment, keys, entry cards, identification badges, telephones, and all documents, files, folders, correspondence, memoranda, notes, notebooks, books, records, promotional materials, plans, forecasts, reports, proposals, agreements, financial information, CDs, thumb drivers, and all other computer-recorded information, as well as all copies thereof, electronic or otherwise.  

9.Proprietary and Confidential Employer Information.  Employee acknowledges that during Employee's employment with Employer, Employee may have had access to confidential or proprietary documents, materials or information regarding Employer’s products, research, business affairs, and personnel matters, which Employee acknowledges and agrees are of a highly sensitive and confidential nature and considered trade secrets and/or proprietary to Employer.  Such information, documents and materials may include, without limitation, trade secrets, inventions, research, plans, proposals, marketing and sales programs, financial projections, cost summaries, pricing formulas and all concepts or ideas, materials or information related to the products, research, business or sales of Employer or Employer’s customers or business partners, as well as Employer’s personnel matters, which has not previously been released to third parties within Employer’s industry or the public at large by an authorized representative of Employer.  Employee represents that Employee has held all such information confidential and will continue to do so, and that Employee will not use such confidential or proprietary information and/or documents for any purpose, specifically including use for any business in the same industry as Employer or in competition with Employer.  Employee understands that this obligation of confidentiality continues indefinitely after Employee’s Separation Date.  Employee also hereby reaffirms Employee’s agreement to, and all of Employee’s obligations under, any proprietary information and inventions agreement previously signed by Employee.  Immunity Notice:  Pursuant to the Defend Trade Secrets Act of 2016, an individual may not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that (a) is

 

2.

 

 

made (i) in confidence to a federal, state or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (b) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. An individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose the trade secret to the attorney of the individual and use the trade secret information in the court proceeding, if the individual (a) files any document containing the trade secret under seal; and (b) does not disclose the trade secret, except pursuant to court order.

10.Applicable Law.  The validity, interpretation and performance of this Agreement shall be construed and interpreted according to the laws of the United States of America and the State of California.

11.Binding on Successors.  The parties agree that this Agreement shall be binding on, and inure to the benefit of, their successors, heirs and/or assigns.

12.Full Defense.  This Agreement may be pled as a full and complete defense to, and may be used as a basis for an injunction against, any action, suit or other proceeding that may be prosecuted, instituted or attempted by Employee in breach hereof.  Employee agrees that in the event an action or proceeding is instituted by the Released Parties in order to enforce the terms or provisions of this Agreement, the Released Parties shall be entitled to an award of reasonable costs and attorneys’ fees incurred in connection with enforcing this Agreement.  This attorneys’ fee provision shall not apply to an action brought by Employee to challenge the enforceability of Employee’s waiver of rights under the Age Discrimination in Employment Act or the Older Workers Benefit Protection Act.

13.Good Faith.  The parties agree to do all things necessary and to execute all further documents necessary and appropriate to carry out and effectuate the terms and purposes of this Agreement.

14.Integration.  This Agreement contains the entire agreement between Employer and the Employee on the subjects addressed in this Agreement and replaces any other prior agreements or representations, whether oral or written, between them; provided, however, that any proprietary or confidential information agreement and/or arbitration agreement Employee signed with Employer remains in full force and effect and is not superseded by this Agreement.  

15.Modification.  This Agreement may be amended only by a written instrument executed by all parties hereto.

16.Section 409(A) of the Internal Revenue Code.  It is intended that all of the benefits and payments under this Agreement satisfy, to the greatest extent possible, the exemptions from the application of Section 409Aof the Internal Revenue Code of 1986, as amended, and the regulations and other guidance thereunder and any state law of similar effect (collectively “Section 409A”) provided under Treasury Regulations 1.409A 1(b)(4) and 1.409A 1(b)(9), and this Agreement will be construed to the greatest extent possible as consistent with those provisions and any ambiguities herein shall be interpreted accordingly. To the extent not so exempt, this Agreement (and any definitions hereunder) will be construed in a manner that complies with Section 409A, and incorporates by reference all required definitions and payment terms.

 

 

Metacrine, Inc.

 

 

By: __________________________________________

       Preston Klassen, President and CEO

 

Address:   3985 Sorrento Valley Blvd, Suite C, San Diego, CA 92121

 

 

Catherine Lee

 

 

By: __________________________________________

       Catherine Lee

 

 


 

3.

 

 

EXHIBIT B

PROPRIETARY INFORMATION AND INVENTIONS AGREEMENT

 

 

4.

 

 EX-101.SCH 3 mtcr-20220125.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 mtcr-20220125_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Entity Registrant Name Entity Registrant Name Document Period End Date Document Period End Date Entity Central Index Key Entity File Number Entity File Number Entity Incorporation State Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, Address Line Two Entity Address Address Line2 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period Security 12b Title Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name EX-101.PRE 5 mtcr-20220125_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.21.4
Document and Entity Information
Jan. 25, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Entity Registrant Name Metacrine, Inc.
Document Period End Date Jan. 25, 2022
Entity Central Index Key 0001634379
Entity File Number 001-39512
Entity Incorporation State Country Code DE
Entity Tax Identification Number 47-2297384
Entity Address, Address Line One 3985 Sorrento Valley Blvd.
Entity Address, Address Line Two Suite C
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92121
City Area Code 858
Local Phone Number 369-7800
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Entity Ex Transition Period true
Security 12b Title Common Stock, par value $0.0001 per share
Trading Symbol MTCR
Security Exchange Name NASDAQ
XML 7 mtcr-8k_20220125_htm.xml IDEA: XBRL DOCUMENT 0001634379 2022-01-25 2022-01-25 false 0001634379 8-K 2022-01-25 Metacrine, Inc. DE 001-39512 47-2297384 3985 Sorrento Valley Blvd. Suite C San Diego CA 92121 858 369-7800 false false false false Common Stock, par value $0.0001 per share MTCR NASDAQ true true EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.4 html 1 122 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.metacrine.com/20220125/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports mtcr-8k_20220125.htm mtcr-20220125.xsd mtcr-20220125_lab.xml mtcr-20220125_pre.xml mtcr-ex991_45.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "mtcr-8k_20220125.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "mtcr-8k_20220125.htm" ] }, "labelLink": { "local": [ "mtcr-20220125_lab.xml" ] }, "presentationLink": { "local": [ "mtcr-20220125_pre.xml" ] }, "schema": { "local": [ "mtcr-20220125.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 122, "memberCustom": 0, "memberStandard": 0, "nsprefix": "mtcr", "nsuri": "http://www.metacrine.com/20220125", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "mtcr-8k_20220125.htm", "contextRef": "C_0001634379_20220125_20220125", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.metacrine.com/20220125/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "mtcr-8k_20220125.htm", "contextRef": "C_0001634379_20220125_20220125", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.metacrine.com/20220125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.metacrine.com/20220125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.metacrine.com/20220125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.metacrine.com/20220125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.metacrine.com/20220125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.metacrine.com/20220125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.metacrine.com/20220125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.metacrine.com/20220125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.metacrine.com/20220125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.metacrine.com/20220125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.metacrine.com/20220125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.metacrine.com/20220125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.metacrine.com/20220125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.metacrine.com/20220125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.metacrine.com/20220125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.metacrine.com/20220125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.metacrine.com/20220125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.metacrine.com/20220125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.metacrine.com/20220125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.metacrine.com/20220125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.metacrine.com/20220125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.metacrine.com/20220125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.metacrine.com/20220125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.metacrine.com/20220125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 14 0001564590-22-003054-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-22-003054-xbrl.zip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end